SmallCap Trading Techniques

[I Like Bottom Fishing]

TRDX News TRDX Announces Completion of Key Milestone and Provides Details on Closing of Definitive Agreement With Genesis Biopharma, Inc.

Friday, September 10, 2010 4:37 PM

Scottrade.com
This email is compliments of Scottrade.com

http://www.otcmarkets.com/stock/TRDX/company-info

http://www.knobias.com/individual/public/quote.htm?ticker=TRDX

http://www.barchart.com/detailedquote/stocks/TRDX

News for 'TRDX' - (TRDX Announces Completion of Key Milestone and Provides Details on Closing of Definitive Agreement With Genesis Biopharma, Inc.)

JERICHO, NY, Sep 10, 2010 (MARKETWIRE via COMTEX) -- SciMeDent Health, Corp.
f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today
confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX")
which will be assigned the Sublicense and upon Final Closing will be 100% owned
by TRDX.

In addition, the Company provides the following details regarding the recently
executed Definitive Sublicense Agreement ("Definitive") with Montreal-based
Genesis Biopharma, Inc. ("Genesis").

General Terms:
Financing TRDX has committed to a financing of $800,000 for the

continued R&D of Genesis' Painful Diabetic Neurapathy

("PDN") solution

The financing can be completed in tranches, with each

tranche resulting in a pro-rated ownership of DiabetRX.



First Tranche $60,000 required to maintain sublicense and take possession

of the first 7.5% of DiabetRX



Initial Closing The Initial Closing is based on, amongst other items, the

completion of customary due diligence by the parties

Final Closing Final Closing is defined as the completion of the $800,000

financing for the development of the PDN solution

Dr. Jan Stahl, CEO of TRDX, commented: "Since the signing of the Definitive
Agreement, I am very happy with the progress we have made with Genesis. We feel
confident in the current steps we are taking to complete the Initial Closing and
first Tranche financing. We view DiabetRX as a long term investment with large
potential and look forward to the Final Closing."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation
founded in 2007 to exploit the commercial potential for the therapeutic use of
peptidomimetic (modified amino acid peptides) compounds. Amino acids are the
building blocks of proteins, which are found in every cell. Proteins consist of
extremely long and complex amino acid chains. In contrast, a peptide is a short
string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of
products and services for medicine, dentistry and life sciences. SciMeDent plans
to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking
statements. These forward-looking statements involve a number of risks and
uncertainties, including the sufficiency of existing capital resources,
technological or industry changes and uncertainties related to the development
of the Company's business model. The actual results the Company may achieve
could differ materially from any forward-looking statements due to such risks
and uncertainties.

Contact:

SciMeDent Health Corp. f/k/a Trend Exploration, Inc.

[e-mail]

1-866-383-1374

SOURCE: Trend Exploration, Inc.

CONTACT: mailto:[e-mail]

Copyright 2010 Marketwire, Inc., All rights reserved.

-0-

SUBJECT CODE: Medical and Healthcare:Alternative

Medical and Healthcare:Dentistry

Medical and Healthcare:Facilities and Providers

Medical and Healthcare:Health and Nutrition

Medical and Healthcare:Healthcare

Medical and Healthcare:Medical Devices

Pharmaceuticals and Biotech:Trials

Medical and Healthcare:Surgery and Treatments

Medical and Healthcare:Nursing

Pharmaceuticals and Biotech:Biotech

Pharmaceuticals and Biotech:Equipment and Supplies

Pharmaceuticals and Biotech:Drugs

Medical and Healthcare:Mental Health

Source: Comtex Wall Street News